Repligen (RGEN) Stock Price, News & Analysis

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings or view top-rated stocks.

9 Wall Street research analysts have issued 12 month price targets for Repligen's shares. Their RGEN share price targets range from $165.00 to $220.00. On average, they expect the company's stock price to reach $196.70 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts.

Repligen's stock was trading at $179.80 at the start of the year. Since then, RGEN stock has decreased by 12.6% and is now trading at $157.06.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our RGEN earnings forecast.

Repligen will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "3623615".

Repligen Co. (NASDAQ:RGEN) released its earnings results on Wednesday, February, 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The biotechnology company earned $155.74 million during the quarter, compared to analysts' expectations of $155.38 million. Repligen had a net margin of 6.51% and a trailing twelve-month return on equity of 5.00%. The business's revenue for the quarter was down 16.6% on a year-over-year basis. During the same period last year, the firm posted $0.68 earnings per share.

ETFs with the largest weight of Repligen (NASDAQ:RGEN) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Biotechnology & Genome ETF (PBE), BlackRock Future Innovators ETF (BFTR), BNY Mellon Innovators ETF (BKIV), Fidelity Disruptive Medicine ETF (FMED), VanEck Biotech ETF (BBH), Nuveen ESG Mid-Cap Growth ETF (NUMG) and WisdomTree BioRevolution Fund (WDNA).

Repligen issued an update on its FY24 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of $1.42-1.49 for the period, compared to the consensus EPS estimate of $1.77. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $660.67 million.

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.60%), Artemis Investment Management LLP (0.30%), Congress Asset Management Co. MA (0.16%), State of Michigan Retirement System (0.02%), Diversified Trust Co (0.01%) and CWM LLC (0.00%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.